| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 5 | |
| #2 | United States | 4 | |
| #3 | Australia | 3 | |
| #4 | Canada | 3 | |
| #5 | China | 2 | |
| #6 | WIPO (World Intellectual Property Organization) | 2 | |
| #7 | Brazil | 1 | |
| #8 | Israel | 1 | |
| #9 | Morocco | 1 | |
| #10 | Mexico | 1 | |
| #11 | New Zealand | 1 | |
| #12 | Tunisia | 1 | |
| #13 | South Africa | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Organic fine chemistry | |
| #4 | Environmental technology |
| # | Name | Total Patents |
|---|---|---|
| #1 | Zagury Jean-Francois | 18 |
| #2 | Bessis Natacha | 6 |
| #3 | Boissier Marie-Christophe | 6 |
| #4 | Montes Matthieu | 3 |
| #5 | Mouhsine Hadley | 3 |
| #6 | Guillemain Helene | 3 |
| #7 | Zagury Jean-François | 2 |
| #8 | Jean-Francois Zagury | 2 |
| #9 | Natacha Bessis | 1 |
| #10 | Francois Zagury Jean | 1 |
| Publication | Filing date | Title |
|---|---|---|
| AU2011213784A1 | Peptides of IL1 BETA and TNF and method of treatment using same | |
| CA2805206A1 | Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf | |
| BRPI0603801A | peptide, peptide derivative, immunogenic compound, use of a peptide or peptide derivative or immunogenic compound, pharmaceutical composition, monoclonal or oligoglonal antibody, use thereof, and methods for treating a disease associated with pathogenic overproduction of il1beta and and for the treatment or prevention of diseases associated with the pathogenic overproduction of il1beta and tnfalfa | |
| WO2005084198A2 | Peptides of il1 beta and tnf alpha and method of treatment using same |